ReviewNature reviews. Endocrinology2024
Arginine vasopressin deficiency: diagnosis, management and the relevance of oxytocin deficiency.
Review in Nature reviews. Endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 30 citations in OpenAlex.
- Bone turnover in arginine vasopressin deficiency: a comparative study with primary polydipsia and healthy controls.The Journal of clinical endocrinology and metabolism · 2026Trial
- The Time of the Hypertonic Saline Infusion Test for the Diagnosis of AVP Deficiency Can Be Shortened With LC-MS/MS.The Journal of clinical endocrinology and metabolism · 2026Trial
- Late recovery from chronic arginine vasopressin deficiency: a multicenter retrospective case-control study.Journal of the Endocrine Society · 2026Article
- Article
- Observational
- Article
- Tirzepatide-associated hyponatremia in a patient with known arginine vasopressin deficiency.JCEM case reports · 2026Article
- Absence of detectable circadian rhythmicity of neurophysin I, a surrogate marker for oxytocin.Pituitary · 2026Article
- Identification of a novel large deletion mutation in theTranslational pediatrics · 2026Article
- Arginine Vasopressin Deficiency and Oxytocin Deficiency in the Endocrine Clinic.The Journal of clinical endocrinology and metabolism · 2026Review
- [Analysis of stimulating factors for serum copeptin based on liquid chromatography-tandem mass spectrometry].Se pu = Chinese journal of chromatography · 2026Article
- In situ encapsulation of Cu-MOF in wax gourd sponge for integrated smart treatment of diabetic wounds.Journal of nanobiotechnology · 2026Article
- The neurobiological regulatory mechanism of brain edema.Frontiers in cellular neuroscience · 2026Review
- Glucagon-stimulated copeptin response in children: a proof-of-concept study.Frontiers in endocrinology · 2026Article
- Editorial: Endocrine regulation of homeostasis of water, electrolytes and organic solutes.Frontiers in endocrinology · 2026Article
- Intravenous kisspeptin 112-121 bolus does not acutely impact circulating vasopressin in humans.Journal of neuroendocrinology · 2026Article
- Drug spectrum and disproportionality signals for diabetes insipidus in FAERS: multi-method analysis, JADER cross-database assessment, and PubMed-based case-level evidence.Frontiers in pharmacology · 2026Article
- Oxytocin: a neglected hormone in pituitary disease - From function to the diagnosis of a deficiency, resulting clinical relevance, and potential treatment options in endocrinology.Archives of endocrinology and metabolism · 2025Review
- Reassessing the Role of Copeptin in Emergency Department Admissions for Hypotonic Hyponatremia.The Journal of clinical endocrinology and metabolism · 2025Article
- The psychedelic-peptide paradox: a hormetic hypothesis.Comprehensive psychoneuroendocrinology · 2025Review
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polyuria-polydipsia syndrome can be caused by central diabetes insipidus, nephrogenic diabetes insipidus or primary polydipsia. To avoid confusion with diabetes mellitus, the name 'central diabetes insipidus' was changed in 2022 to arginine vasopressin (AVP) deficiency and 'nephrogenic diabetes insipidus' was renamed as AVP resistance. To differentiate the three entities, various osmotic and non-osmotic copeptin-based stimulation tests have been introduced in the past decade. The hypertonic saline test plus plasma copeptin measurement emerged as the test with highest diagnostic accuracy, replacing the water deprivation test as the gold standard in differential diagnosis of the polyuria-polydipsia syndrome. The mainstay of treatment for AVP deficiency is AVP replacement with desmopressin, a synthetic analogue of AVP specific for AVP receptor 2 (AVPR2), which usually leads to rapid improvements in polyuria and polydipsia. The main adverse effect of desmopressin is dilutional hyponatraemia, which can be reduced by regularly performing the so-called desmopressin escape method. Evidence from the past few years suggests an additional oxytocin deficiency in patients with AVP deficiency. This potential deficiency should be further evaluated in future studies, including feasible provocation tests for clinical practice and interventional trials with oxytocin substitution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.